In this issue of Cell, Lu et al. provide important insights on the efficacy of human antibodies to Mycobacterium tuberculosis and on how functional heterogeneity of the antibody response may explain a century of contradictory evidence for the role of humoral immunity in defense against tuberculosis.
At the dawn of immunology there was a colossal debate between proponents of humoral and cellular immunity as to the relative importance of the two immune arms (Silverstein, 1979) . The humoral school championed antibody as the mediator of immunity, while the cellular school championed phagocytic cells as the key mediator of host defense, with antibody being an auxiliary component relegated primarily to promoting opsonization. By the early decades of the 20th century, the humoralist's view prevailed, but there were problems with the theory: some hosts had specific antibody but were susceptible, and it was difficult to prove the importance of antibody by passive transfer experiments against certain microbes, including a very important human pathogen, the Mycobacterium tuberculosis (Mtb) bacterium. Since the 1890s, many studies suggested that humoral immunity protected against tuberculosis with inconsistent results (Glatman-Freedman and Casadevall, 1998) . By the 1940s, the phagocytic theory was reformulated as tissue immunity which posited that granuloma formation protected against those microbes for which it was difficult to show the efficacy of humoral immunity, including intracellular bacterial pathogens and fungi. Hence, universal views of immunity were replaced with sectarian views that assigned responsibility for protection to different arms of the immune system, a paradigm that persisted into the 1990s (Figure 1) .
A role for humoral immunity in host defense against a microbe is established by: (1) passive antibody experiments that confer protection; (2) an association between serum antibodies and resistance to infection; and (3) an association between disease and humoral immunodeficiency. In the case of Mtb, these criteria have provided inconsistent evidence for a role for antibodies in host defense (Achkar and Casadevall, 2013) . Passive protection experiments showed protection in some cases, but not others, brisk antibody responses occurred in diseased individuals, and there has been no obvious association between tuberculosis and humoral immunodeficiency. On the other hand, host defense against mycobacteria is associated with granuloma formation, which is representative of cellular immunity, and T cell defects are associated with severe disease. However, often forgotten in the debate was the fact that these criteria are informative only when the result is positive since negative effects do not exclude the possibility that protective Ab responses exist. Similarly, the absence of cases in association with humoral immunodeficiency could be explained by redundant cell-mediated immunity, which in turn does not exclude a role for Ab in host defense. These caveats seem to have been ignored and, consequently, the tuberculosis field neglected the study of humoral immunity for decades. As such, the word ''controversial'' is often associated with discussions about the role of antibodies in defense against mycobacteria.
The development of hybridoma technology in the late 20th century provided a new tool to explore the potential of humoral immunity. In contrast to polyclonal preparations in which the pathogen-specific antibody only constituted a fraction of the total protein, monoclonal antibody (mAb) preparations originated from individual B cells such that all immunoglobulins had one identical affinity, specificity, and isotype, allowing one to study the efficacy of individual Abs. By the end of the 1990s, protective mAbs had been made against several fungi and numerous intracellular bacterial pathogens including Mtb. In fact, protective, non-protective, and even disease-enhancing mAbs had been described implying that efficacy of a given immune sera was the sum of these activities. This suggested that the problem in demonstrating the efficacy of humoral immunity was not due to inherent limitation of antibodies per se but rather related to the phenomenon that many of these pathogens elicited non-protective antibodies. Although medical mycology rapidly adapted this new position, the field of tuberculosis took a much longer time to accept the existence of protective antibodies despite reports of protective Abs from several independent groups (Achkar and Casadevall, 2013) .
Against this complex historical backdrop of controversy, the paper by Lu et al. (2016) provides important new information supportive of the notion that the uncertainty in establishing a role for Ab in protection reflects the functional heterogeneity of the antibody response. These investigators report that antibodies made by individuals with latent disease are functionally superior from those with active tuberculosis in promoting phagolysosomal fusion, inflammasome activation, and macrophage killing of internalized mycobacteria. The results establish qualitative differences in the antibody response between diseased and healthy infected individuals and implicate differences in antibody glycosylation in function. However, we still do not know whether these differences reflect causes or effects. The finding of functionally superior antibodies in individuals with latent Tb supports the notion that those who make better antibodies are able to control infection and avoid disease. On the other hand, the progression to disease with a high antigenic burden and chronic inflammatory response could result in the production of less effective antibodies as the immune response evolves. Another unresolved question is whether the functional differences of these antibodies also reflect differences in specificity. Irrespective of whether these associations are causative or correlative, these findings provide a handle for investigating such questions and promise to catalyze a change in the research landscape by refocusing antibody studies from quantitative to qualitative assessments. This represents real progress in this field and encourages new studies to find the elusive correlates protection that could be used in designing new vaccines. In the big picture the results of Lu et al. (2016) could be important in bringing balance to the study of immunity against tuberculosis, which has largely ignored the contribution of antibodies despite the reasonableness of the notion that both immune arms contribute to host defense.
